Patent Highlights February–March 2019

Abstract

Use of substance directly or indirectly regulating YB-1 phosphorylation in preparation of drug for treating disease caused by inflammatory factors Inventors: Liu B Assignee: Jilin Zhong Tai Biotechnological Co. Ltd, Changchun (Jilin, China) Y-box binding proteins are multifunctional nucleic acid-binding proteins with an evolutionary conserved cold shock domain. Their dysregulated expression can influence transcription and translation on many levels and has been linked to cancer and inflammatory diseases [1]. The best investigated Y-box binding protein, YB-1 (also known as YBX1), locates to cytoplasmic P granules and stress granules, and is considered a target for drug-resistant cancer therapy [2]. The signaling pathways involved in stress-induced YB-1 phosphorylation have recently been described [3]. It is well known that YB-1 is an early and central mediator of noncancer inflammation, especially in the context of renal conditions [4,5]. The inventor claims MK-2206 (an allosteric Akt inhibitor for which the US National Cancer Institute had completed a Phase II clinical study in 2017) and dexamethasone as agents that control YB-1 phosphorylation (and hence, inflammation of almost any type) either directly or indirectly (through phosphorylation of YB-1 inhibitors). Data from experiments with fresh human arterial tissue and murine arteriosclerosis models are presented.